文献速递消化系统肿瘤

胰腺癌简约风险分层模型的开发与验证

Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.
PubMed 文献 · JAMA Oncol · 2026-01-01

本研究利用美国电子健康记录数据开发并验证了简约且可解释的胰腺导管腺癌(PDAC)风险预测模型PRIME。训练队列含23个卫生系统4 859 833人,验证队列含31个系统5 619 091人,并在英国生物银行498 754人中开展国际验证。模型保留19个预测因子,36个月AUC在训练和验证队列均为0.75,验证队列中预测风险最高1%者的PDAC风险显著增高(HR 7.63,95%CI 6.85-8.49)。

要点

  • PRIME模型仅用常规EHR数据即可预测36个月内PDAC风险,AUC为0.75。
  • 验证队列中预测风险最高1%者PDAC风险是平均风险者的7.63倍。
  • 英国生物银行国际验证36个月AUC为0.71,校准良好。

核心结论

  • PRIME是基于EHR的透明模型,能在美国多卫生系统及国际人群中有效分层PDAC风险,支持EHR引导的病例发现及与血液早筛检测的整合。

研究设计与样本

  • 队列研究,使用Optum Labs数据仓库2016-2018年40岁及以上有门诊就诊的成年人。
  • 训练队列来自23个卫生系统(n=4 859 833),验证队列来自31个系统(n=5 619 091)。
  • 国际验证在英国生物银行(n=498 754)中进行。

主要发现

  • 训练队列平均随访5.4年,14 405人诊断PDAC,发病率55/100 000人年。
  • 验证队列平均随访3.9年,11 693人诊断PDAC,发病率54/100 000人年。
  • 36个月时间 horizon 训练与验证队列AUC均为0.75,校准良好。
  • 验证队列中预测风险最高1%者PDAC风险显著高于平均风险者(HR 7.63;95%CI 6.85-8.49)。
  • 英国生物银行中PRIME的36个月AUC为0.71,校准良好。

关键数值与推荐

  • PRIME保留19个预测因子,包括胰腺炎史、胃肠道疾病、既往癌症、2型糖尿病、天冬氨酸氨基转移酶升高、吸烟、非O型血和男性。

临床怎么用

  • 可利用常规EHR数据计算PRIME风险评分,识别PDAC高风险个体。
  • 高风险个体可考虑进一步评估或参与EHR引导的病例发现研究。

局限性

  • PDAC结局基于ICD-9/10编码识别,可能存在错分。
  • 研究为回顾性队列,需前瞻性研究验证EHR引导的病例发现效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the US. Although early detection improves survival, the rarity of the disease has rendered population screening a difficult approach. OBJECTIVE: To develop and validate a parsimonious, interpretable, and generalizable model predicting incident PDAC-termed PRIME (PDAC Risk Model for Earlier Detection)-using routinely available electronic health record (EHR) data. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Optum Labs Data Warehouse, a longitudinal, deidentified US EHR and claims database. Adults 40 years or older with an outpatient clinical encounter between 2016 and 2018 were included. Participants from 23 health systems (n = 4 859 833) comprised the training cohort; 31 additional systems (n = 5 619 091) served as validation. International validation was conducted in the UK Biobank (n = 498 754). Data analysis occurred July 2025 to January 2026. EXPOSURES: Demographics, diagnosis codes, and routinely measured laboratory values were evaluated. Elastic-net regularization with 10-fold cross-validation selected the predictor set. MAIN OUTCOMES AND MEASURES: Incident PDAC was identified by International Classification of Diseases, Ninth and Tenth Revisions (ICD-9/10) codes. Model performance was assessed using time-dependent area under the curve (AUC) and calibration metrics. RESULTS: Overall, the study included more than 11 million adults (2.1% Asian individuals, 8.4% Black individuals, 4.3% Hispanic/Latino individuals, 82.7% White individuals, and 2.4% other race/ethnicity by EHR reporting). In the training cohort (mean [SD] age, 60.4 [11] years), 14 405 individuals were diagnosed with PDAC (incidence 55 per 100 000 person-years) over a mean (SD) of 5.4 (2.5) years; in the validation cohort, 11 693 individuals were diagnosed with PDAC (54 per 100 000 person-years) over a mean (SD) of 3.9 (2.5) years. PRIME retained 19 predictors including history of pancreatitis, gastrointestinal disorders, prior cancers, type 2 diabetes, elevated aspartate aminotransferase levels, smoking, non-type-O blood, and male sex. Discrimination was strong at the 36-month time horizon (AUC = 0.75 in both the training and validation cohorts) with good calibration. In the validation cohort, patients in the top 1% of predicted risk had substantially higher PDAC risk (HR, 7.63; 95% CI, 6.85-8.49) compared with average-risk patients. In the UK Biobank, PRIME achieved a 36-month AUC of 0.71 with good calibration. CONCLUSIONS AND RELEVANCE: In this validation cohort study, PRIME was a transparent EHR-based model that effectively stratified PDAC risk across diverse US health systems and generalized internationally. Prospective studies should evaluate for EHR-guided PDAC case-finding and integration with blood-based early-detection assays.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mavromatis LA, Zlatanic V, Agarunov E, et al. Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer. JAMA Oncol. 2026. PMID: 41885821. doi:10.1001/jamaoncol.2026.0372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。